<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538070</url>
  </required_header>
  <id_info>
    <org_study_id>1R01DA022276-01</org_study_id>
    <secondary_id>1R01DA022276</secondary_id>
    <secondary_id>#2007-P-000416/1</secondary_id>
    <secondary_id>R01DA022276</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00538070</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of Sarcosine on Symptoms and Brain Glycine Levels in People With Schizophrenia</brief_title>
  <acronym>Sarc</acronym>
  <official_title>The Effects of Glycine Transport Inhibition on Brain Glycine Concentration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NMDA receptor has been identified as having a role in substance use disorders as well as
      in schizophrenia. One example of the former is nicotine's effect on dopaminergic activity not
      only by increasing the release of dopamine in the Midbrain reward centers, but also through
      less direct mechanisms affecting alpha-7 nicotinic receptors, NMDA receptors, and Glycine, a
      co-agonist for the NMDA receptors. In terms of schizophrenia, it has been hypothesized that
      NMDA receptor hypofunction plays a role in the mechanism for negative symptoms and cognitive
      dysfunction in these patients. The NMDA hypofunction may be reversed with increased synaptic
      glycine availability.

      Sarcosine, or n-methyl-glycine, is a GlyT-1 and System A transport inhibitor actions which
      could be expected to increase the availability of glycine, in the synaptic space. Sarcosine
      is a dietary supplement which could be found in several food items such as egg yolks and
      turkey.

      Our collaborative team has developed a novel, non-invasive magnetic resonance spectroscopy
      (MRS) technique for measuring brain glycine changes that allows us to study glycine
      homeostasis. The purpose of this study is to explore the effect of sarcosine
      (n-methyl-glycine) on brain glycine concentrations. It is our hypothesis that oral sarcosine,
      at a dose of 2 grams per day, will be well tolerated and associated with increased brain
      glycine concentrations. It is our secondary exploratory hypothesis that increases in brain
      glycine will be associated with behavioral signs of increased NMDA and dopamine activity.
      This modulation could have future therapeutic potential for disorders of hedonic and
      cognitive function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Research subjects will undergo a screening visit at the Massachusetts General Hospital Center
      for Addiction Medicine. If they meet inclusion criteria, they will be invited for the
      baseline visit when they will have their first MRS and will begin taking the study
      drug/placebo. The randomization will be done in blocks of four. The study drug/placebo is
      prescribed to take 2 capsules of 500 mg each, two times per day, with or without food. They
      will continue weekly visits for six weeks and will receive new supplies of the study
      drug/placebo on weeks 2 and 4. On week 6, they will have the second MRS. On weeks 8 and 16,
      subjects will undergo follow up visits. On several of these visits, study staff will assess
      for the presence of adverse events (with the UKU instrument), cigarettes use (with carbon
      monoxide monitoring), and abnormal involuntary movements (with the abnormal involuntary
      movement scale, the barnes akathisia scale, and the sympson angus scale).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increases in brain glycine concentration as measured by magnetic resonance spectroscopy</measure>
    <time_frame>baseline and endpoint</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>You will receive two grams of placebo per day. You will take two 500 mg placebo capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sarcosine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>You will receive two grams of sarcosine per day. You will take two 500 mg capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sarcosine</intervention_name>
    <description>You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sarcosine</arm_group_label>
    <other_name>glycine transport inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Women and men aged 18-65 with DSM-IV diagnosis of schizophrenia or schizoaffective
             disorder by diagnostic interview and chart review.

          2. Clinically stable on a stable dose of antipsychotic medication for at least one month,
             no current active suicidal ideation.

          3. Competent to provide informed consent.

          4. Women of childbearing age must have a negative pregnancy test at screening and agree
             to use an approved form of contraception throughout the study.

          5. Screening labs within normal limits for age and gender except for liver function tests
             as specified below.

        EXCLUSION CRITERIA:

          1. Diagnosis of bipolar disorder, dementia, neurodegenerative disease, or other organic
             mental disorder.

          2. History of seizure disorder or CNS tumor.

          3. Liver function tests elevated over twice normal.

          4. Bulimia, or major depressive disorder within the last 6 months.

          5. Life-threatening arrhythmia, cerebro-vascular, or cardiovascular event within 6
             months. Current serious unstable medical illness including cardiovascular, hepatic,
             renal, respiratory, endocrine, neurological, or hematological disease such that
             hospitalization for treatment of that illness is likely within the next 2 months.
             Lifetime history of multiple head injuries with neurological sequelae or a single
             severe head injury with lasting neurological sequelae.

          6. Use of investigational medication within 30 days of enrollment.

          7. Use of clozapine.

          8. Substance use disorder other than nicotine or caffeine in the last 6 months (by self
             report and salivary drug and alcohol screen).

          9. Posing a current risk of homicide or suicide.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Eden Evins, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Kaufman, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McLean Hospital, Brain Imaging Center</name>
      <address>
        <city>Belmont</city>
        <state>Massachusetts</state>
        <zip>02478</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MGH Center for Addiction Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Berger AJ, Dieudonné S, Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol. 1998 Dec;80(6):3336-40.</citation>
    <PMID>9862928</PMID>
  </reference>
  <reference>
    <citation>Mansvelder HD, McGehee DS. Long-term potentiation of excitatory inputs to brain reward areas by nicotine. Neuron. 2000 Aug;27(2):349-57.</citation>
    <PMID>10985354</PMID>
  </reference>
  <reference>
    <citation>López E, Arce C, Vicente S, Oset-Gasque MJ, González MP. Nicotinic receptors mediate the release of amino acid neurotransmitters in cultured cortical neurons. Cereb Cortex. 2001 Feb;11(2):158-63.</citation>
    <PMID>11208670</PMID>
  </reference>
  <reference>
    <citation>Lim DK, Park SH, Choi WJ. Subacute nicotine exposure in cultured cerebellar cells increased the release and uptake of glutamate. Arch Pharm Res. 2000 Oct;23(5):488-94.</citation>
    <PMID>11059829</PMID>
  </reference>
  <reference>
    <citation>McGehee DS, Heath MJ, Gelber S, Devay P, Role LW. Nicotine enhancement of fast excitatory synaptic transmission in CNS by presynaptic receptors. Science. 1995 Sep 22;269(5231):1692-6.</citation>
    <PMID>7569895</PMID>
  </reference>
  <reference>
    <citation>Toth E, Vizi ES, Lajtha A. Effect of nicotine on levels of extracellular amino acids in regions of the rat brain in vivo. Neuropharmacology. 1993 Aug;32(8):827-32.</citation>
    <PMID>8105411</PMID>
  </reference>
  <reference>
    <citation>Toth E. Effect of nicotine on the level of extracellular amino acids in the hippocampus of rat. Neurochem Res. 1996 Aug;21(8):903-7.</citation>
    <PMID>8895843</PMID>
  </reference>
  <reference>
    <citation>McBain CJ, Kleckner NW, Wyrick S, Dingledine R. Structural requirements for activation of the glycine coagonist site of N-methyl-D-aspartate receptors expressed in Xenopus oocytes. Mol Pharmacol. 1989 Oct;36(4):556-65.</citation>
    <PMID>2554111</PMID>
  </reference>
  <reference>
    <citation>Herdon HJ, Godfrey FM, Brown AM, Coulton S, Evans JR, Cairns WJ. Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes. Neuropharmacology. 2001 Jul;41(1):88-96.</citation>
    <PMID>11445189</PMID>
  </reference>
  <reference>
    <citation>Sakata K, Sato K, Schloss P, Betz H, Shimada S, Tohyama M. Characterization of glycine release mediated by glycine transporter 1 stably expressed in HEK-293 cells. Brain Res Mol Brain Res. 1997 Oct 3;49(1-2):89-94.</citation>
    <PMID>9387867</PMID>
  </reference>
  <reference>
    <citation>Javitt DC, Duncan L, Balla A, Sershen H. Inhibition of system A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action. Mol Psychiatry. 2005 Mar;10(3):275-87.</citation>
    <PMID>15278098</PMID>
  </reference>
  <reference>
    <citation>Lechner SM. Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol. 2006 Feb;6(1):75-81. Epub 2005 Dec 22. Review.</citation>
    <PMID>16376148</PMID>
  </reference>
  <reference>
    <citation>Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, Bergeron R. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol. 2004 Jun 1;557(Pt 2):489-500. Epub 2004 Apr 2.</citation>
    <PMID>15064326</PMID>
  </reference>
  <reference>
    <citation>Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004 Mar 1;55(5):452-6.</citation>
    <PMID>15023571</PMID>
  </reference>
  <reference>
    <citation>Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry. 2005 Nov;62(11):1196-204.</citation>
    <PMID>16275807</PMID>
  </reference>
  <reference>
    <citation>Gannon MC, Nuttall JA, Nuttall FQ. The metabolic response to ingested glycine. Am J Clin Nutr. 2002 Dec;76(6):1302-7.</citation>
    <PMID>12450897</PMID>
  </reference>
  <reference>
    <citation>Gibbs M, Fullerton T, Abi-Saab W, Gibbs J, Sweeney F, Soares H, McLellan T, Palmieri T, Yones C, Kim E, Moran S, Jhee S, Ereshefsky L: Cerebrospinal Fluid and Plasma Pharmacokinetics of Glycine and Serine in Healthy Volunteers after Administration of Oral Glycine, in American Association of Pharmaceutical Scientists Nashville, Tn. Nashville, Tn, 2005</citation>
  </reference>
  <reference>
    <citation>Rabe CS, Tabakoff B. Glycine site-directed agonists reverse the actions of ethanol at the N-methyl-D-aspartate receptor. Mol Pharmacol. 1990 Dec;38(6):753-7.</citation>
    <PMID>1701211</PMID>
  </reference>
  <reference>
    <citation>Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am J Psychiatry. 2005 Sep;162(9):1738-40.</citation>
    <PMID>16135636</PMID>
  </reference>
  <reference>
    <citation>Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res. 2004 Nov 1;71(1):103-12.</citation>
    <PMID>15374578</PMID>
  </reference>
  <reference>
    <citation>Evins AE, Amico ET, Shih V, Goff DC. Clozapine treatment increases serum glutamate and aspartate compared to conventional neuroleptics. J Neural Transm (Vienna). 1997;104(6-7):761-6.</citation>
    <PMID>9444574</PMID>
  </reference>
  <reference>
    <citation>Linnér L, Wiker C, Wadenberg ML, Schalling M, Svensson TH. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology. 2002 Nov;27(5):691-8.</citation>
    <PMID>12431844</PMID>
  </reference>
  <reference>
    <citation>Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000 May;157(5):826-8.</citation>
    <PMID>10784481</PMID>
  </reference>
  <reference>
    <citation>Potkin SG, Jin Y, Bunney BG, Costa J, Gulasekaram B. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia. Am J Psychiatry. 1999 Jan;156(1):145-7.</citation>
    <PMID>9892314</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996 Dec;153(12):1628-30.</citation>
    <PMID>8942463</PMID>
  </reference>
  <reference>
    <citation>Supplisson S, Bergman C. Control of NMDA receptor activation by a glycine transporter co-expressed in Xenopus oocytes. J Neurosci. 1997 Jun 15;17(12):4580-90.</citation>
    <PMID>9169519</PMID>
  </reference>
  <reference>
    <citation>Aubrey KR, Vandenberg RJ, Clements JD. Dynamics of forward and reverse transport by the glial glycine transporter, glyt1b. Biophys J. 2005 Sep;89(3):1657-68. Epub 2005 Jun 10.</citation>
    <PMID>15951392</PMID>
  </reference>
  <reference>
    <citation>Schwarcz R, Rassoulpour A, Wu HQ, Medoff D, Tamminga CA, Roberts RC. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry. 2001 Oct 1;50(7):521-30.</citation>
    <PMID>11600105</PMID>
  </reference>
  <reference>
    <citation>Aprison MH, Shank RP, Davidoff RA. A comparison of the concentration of glycine, a transmitter suspect, in different areas of the brain and spinal cord in seven different vertebrates. Comp Biochem Physiol. 1969 Mar;28(3):1345-55.</citation>
    <PMID>5786830</PMID>
  </reference>
  <reference>
    <citation>Gundlach AL, Beart PM. Neurochemical studies of the mesolimbic dopaminergic pathway: glycinergic mechanisms and glycinergic-dopaminergic interactions in the rat ventral tegmentum. J Neurochem. 1982 Feb;38(2):574-81.</citation>
    <PMID>7108557</PMID>
  </reference>
  <reference>
    <citation>Toth E, Lajtha A. Elevation of cerebral levels of nonessential amino acids in vivo by administration of large doses. Neurochem Res. 1981 Dec;6(12):1309-17.</citation>
    <PMID>6122166</PMID>
  </reference>
  <reference>
    <citation>Viola A, Chabrol B, Nicoli F, Confort-Gouny S, Viout P, Cozzone PJ. Magnetic resonance spectroscopy study of glycine pathways in nonketotic hyperglycinemia. Pediatr Res. 2002 Aug;52(2):292-300.</citation>
    <PMID>12149509</PMID>
  </reference>
  <reference>
    <citation>Prescot AP, de B Frederick B, Wang L, Brown J, Jensen JE, Kaufman MJ, Renshaw PF. In vivo detection of brain glycine with echo-time-averaged (1)H magnetic resonance spectroscopy at 4.0 T. Magn Reson Med. 2006 Mar;55(3):681-6.</citation>
    <PMID>16453318</PMID>
  </reference>
  <reference>
    <citation>Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001 Dec;4(4):385-91.</citation>
    <PMID>11806864</PMID>
  </reference>
  <reference>
    <citation>Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry. 1994 Aug;151(8):1234-6.</citation>
    <PMID>8037263</PMID>
  </reference>
  <reference>
    <citation>Leiderman E, Zylberman I, Zukin SR, Cooper TB, Javitt DC. Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial. Biol Psychiatry. 1996 Feb 1;39(3):213-5.</citation>
    <PMID>8837983</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996 Nov;169(5):610-7.</citation>
    <PMID>8932891</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res. 2004 Feb 1;66(2-3):89-96.</citation>
    <PMID>15061240</PMID>
  </reference>
  <reference>
    <citation>Pich EM, Chiamulera C, Tessari M. Neural substrate of nicotine addiction as defined by functional brain maps of gene expression. J Physiol Paris. 1998 Jun-Aug;92(3-4):225-8.</citation>
    <PMID>9789813</PMID>
  </reference>
  <reference>
    <citation>Brody AL, Mandelkern MA, Lee G, Smith E, Sadeghi M, Saxena S, Jarvik ME, London ED. Attenuation of cue-induced cigarette craving and anterior cingulate cortex activation in bupropion-treated smokers: a preliminary study. Psychiatry Res. 2004 Apr 30;130(3):269-81. Erratum in: Psychiatry Res. 2004 Dec 15;132(2):183-4.</citation>
    <PMID>15135160</PMID>
  </reference>
  <reference>
    <citation>Ashton L, Barnes A, Livingston M, Wyper D; Scottish Schizophrenia Research Group. Cingulate abnormalities associated with PANSS negative scores in first episode schizophrenia. Behav Neurol. 2000;12(1-2):93-101.</citation>
    <PMID>11455046</PMID>
  </reference>
  <reference>
    <citation>Ogg RJ, Kingsley PB, Taylor JS. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. J Magn Reson B. 1994 May;104(1):1-10.</citation>
    <PMID>8025810</PMID>
  </reference>
  <reference>
    <citation>Kaufman MJ, Henry ME, Frederick Bd, Hennen J, Villafuerte RA, Stoddard EP, Schmidt ME, Cohen BM, Renshaw PF. Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry. 2003 Sep 1;54(5):534-9.</citation>
    <PMID>12946882</PMID>
  </reference>
  <reference>
    <citation>Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993 Dec;30(6):672-9.</citation>
    <PMID>8139448</PMID>
  </reference>
  <reference>
    <citation>Jensen JE, Frederick Bde B, Renshaw PF. Grey and white matter GABA level differences in the human brain using two-dimensional, J-resolved spectroscopic imaging. NMR Biomed. 2005 Dec;18(8):570-6.</citation>
    <PMID>16273508</PMID>
  </reference>
  <reference>
    <citation>Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993 Dec;(22):39-44.</citation>
    <PMID>8110442</PMID>
  </reference>
  <reference>
    <citation>Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988 Nov;26(2):223-38.</citation>
    <PMID>3237915</PMID>
  </reference>
  <reference>
    <citation>Waters AJ, Shiffman S, Sayette MA, Paty JA, Gwaltney CJ, Balabanis MH. Attentional bias predicts outcome in smoking cessation. Health Psychol. 2003 Jul;22(4):378-87.</citation>
    <PMID>12940394</PMID>
  </reference>
  <reference>
    <citation>Williams JM, Mathews A, MacLeod C. The emotional Stroop task and psychopathology. Psychol Bull. 1996 Jul;120(1):3-24. Review.</citation>
    <PMID>8711015</PMID>
  </reference>
  <reference>
    <citation>Waters AJ, Shiffman S, Bradley BP, Mogg K. Attentional shifts to smoking cues in smokers. Addiction. 2003 Oct;98(10):1409-17.</citation>
    <PMID>14519178</PMID>
  </reference>
  <reference>
    <citation>al-Adawi S, Powell J. The influence of smoking on reward responsiveness and cognitive functions: a natural experiment. Addiction. 1997 Dec;92(12):1773-82.</citation>
    <PMID>9581009</PMID>
  </reference>
  <reference>
    <citation>Irving JM, Clark EC, Crombie IK, Smith WC. Evaluation of a portable measure of expired-air carbon monoxide. Prev Med. 1988 Jan;17(1):109-15.</citation>
    <PMID>3362796</PMID>
  </reference>
  <reference>
    <citation>Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-9.</citation>
    <PMID>4917967</PMID>
  </reference>
  <reference>
    <citation>Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989 May;154:672-6.</citation>
    <PMID>2574607</PMID>
  </reference>
  <reference>
    <citation>Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.</citation>
    <PMID>2887090</PMID>
  </reference>
  <reference>
    <citation>Marx CE, Trost WT, Shampine L, Behm FM, Giordano LA, Massing MW, Rose JE. Neuroactive steroids, negative affect, and nicotine dependence severity in male smokers. Psychopharmacology (Berl). 2006 Jun;186(3):462-72. Epub 2006 Jan 10.</citation>
    <PMID>16402195</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999 Feb 15;45(4):512-4.</citation>
    <PMID>10071726</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999 Jan;56(1):29-36.</citation>
    <PMID>9892253</PMID>
  </reference>
  <reference>
    <citation>Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002 Mar;159(3):480-2.</citation>
    <PMID>11870017</PMID>
  </reference>
  <reference>
    <citation>Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1;44(11):1081-9.</citation>
    <PMID>9836012</PMID>
  </reference>
  <reference>
    <citation>Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1822-5.</citation>
    <PMID>10553752</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr;179(1):144-50. Epub 2004 Oct 21.</citation>
    <PMID>15502972</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999 Jan;56(1):21-7.</citation>
    <PMID>9892252</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Tsai G, Manoach DS, Coyle JT. Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry. 1995 Aug;152(8):1213-5.</citation>
    <PMID>7625475</PMID>
  </reference>
  <reference>
    <citation>Evins AE, Amico E, Posever TA, Toker R, Goff DC. D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res. 2002 Jul 1;56(1-2):19-23.</citation>
    <PMID>12084415</PMID>
  </reference>
  <reference>
    <citation>Farber NB, Newcomer JW, Olney JW. Glycine agonists: what can they teach us about schizophrenia? Arch Gen Psychiatry. 1999 Jan;56(1):13-7. Review.</citation>
    <PMID>9892251</PMID>
  </reference>
  <reference>
    <citation>Shoham S, Javitt DC, Heresco-Levy U. Chronic high-dose glycine nutrition: effects on rat brain cell morphology. Biol Psychiatry. 2001 May 15;49(10):876-85.</citation>
    <PMID>11343684</PMID>
  </reference>
  <reference>
    <citation>Eschenbrenner M, Jorns MS. Cloning and mapping of the cDNA for human sarcosine dehydrogenase, a flavoenzyme defective in patients with sarcosinemia. Genomics. 1999 Aug 1;59(3):300-8.</citation>
    <PMID>10444331</PMID>
  </reference>
  <reference>
    <citation>Levy HL, Coulombe JT, Benjamin R. Massachusetts Metabolic Disorders Screening Program: III. Sarcosinemia. Pediatrics. 1984 Oct;74(4):509-13.</citation>
    <PMID>6207480</PMID>
  </reference>
  <reference>
    <citation>Harding CO, Williams P, Pflanzer DM, Colwell RE, Lyne PW, Wolff JA. sar: a genetic mouse model for human sarcosinemia generated by ethylnitrosourea mutagenesis. Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2644-8.</citation>
    <PMID>1372986</PMID>
  </reference>
  <reference>
    <citation>Gomeza J, Hülsmann S, Ohno K, Eulenburg V, Szöke K, Richter D, Betz H. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition. Neuron. 2003 Nov 13;40(4):785-96. Erratum in: Neuron. 2004 Feb 19;41(4):675.</citation>
    <PMID>14622582</PMID>
  </reference>
  <reference>
    <citation>Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, Jiang Z, Caine SB, Coyle JT. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8485-90. Epub 2004 May 24.</citation>
    <PMID>15159536</PMID>
  </reference>
  <reference>
    <citation>Pearl PL, Capp PK, Novotny EJ, Gibson KM. Inherited disorders of neurotransmitters in children and adults. Clin Biochem. 2005 Dec;38(12):1051-8. Epub 2005 Nov 18. Review.</citation>
    <PMID>16298354</PMID>
  </reference>
  <reference>
    <citation>Hughes JR, Higgins ST, Bickel WK. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction. 1994 Nov;89(11):1461-70. Review.</citation>
    <PMID>7841857</PMID>
  </reference>
  <reference>
    <citation>Patten CA, Martin JE. Measuring tobacco withdrawal: a review of self-report questionnaires. J Subst Abuse. 1996;8(1):93-113. Review.</citation>
    <PMID>8743771</PMID>
  </reference>
  <reference>
    <citation>Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry. 2002 Mar 15;51(6):493-7.</citation>
    <PMID>11922885</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <last_update_submitted>September 17, 2012</last_update_submitted>
  <last_update_submitted_qc>September 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>A. Eden Evins</investigator_full_name>
    <investigator_title>Associate Professor of Psychiatry and Director of the MGH Center for Addiction Medicine</investigator_title>
  </responsible_party>
  <keyword>Sarcosine</keyword>
  <keyword>Glycine</keyword>
  <keyword>Magnetic Resonance Spectroscopy</keyword>
  <keyword>Schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

